Crescent Biopharma, Inc. (CBIO) Fair Value 2026

CBIO · Biotechnology ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

4.7 /10

32 fundamental signals · 1 models active

Value Trap Risk

LOW (32/100)

Quick Summary — As of 2026-08-28, Crescent Biopharma, Inc. (CBIO) trades at $17.75. QOC: 4.7/10. Value Trap Risk: 32/100 (LOW). 1/13 models active.

Key Facts

Ticker
CBIO
Price
$17.75
Quality Score
4.7/10
Value Trap Risk
32/100
Models Active
1/13
Last Updated
Strength: 1 independent models provide multi-angle coverage
Risk: Below-average Quality Score of 4.7/10 signals weak fundamentals

What Fair Value Does Each Model Give CBIO?

1 Intrinsic Value Models vs. Current Price ($17.75)

Core Models (Unlocked)
Model Fair Value Upside
Intrinsic · Medium Conviction
 $2.80 -84.2%

All Models Active

All 1 models are displayed above.

What Is Crescent Biopharma, Inc. (CBIO) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, Crescent Biopharma, Inc.'s intrinsic value is estimated at $2.80, suggesting the stock is overvalued at its current price of $17.75. With 1 out of 1 models flagging downside (-84.2% vs price), the market may be pricing in unsustainable growth.

What Do the Models Say About CBIO?

1 of 13 models are currently active for CBIO. All 1 active models suggest the stock trades above fair value. See which stocks rank higher →

How Does CBIO Rank in Biotechnology?

Among 625 Biotechnology stocks, CBIO ranks #398 by Quality of Company score. CirclFi's QOC score of 4.7/10 evaluates 32 fundamental signals. A score of 4.7 reflects mixed fundamentals.

See all Most Undervalued Biotechnology Stocks →

Within the Biotechnology space, Crescent Biopharma, Inc. competes in an environment where partnership revenue often separates market leaders from laggards. Understanding these industry-specific dynamics is essential context for interpreting our model outputs.

Is CBIO a Value Trap?

CirclFi's Value Trap algorithm assigns CBIO a score of 32/100 (LOW). This indicates low risk. The financial profile does not exhibit typical value trap warning signs. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

1 of 13 models are active for Crescent Biopharma, Inc.. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Quality of Company (QOC) framework, which evaluates 32 signals including margin stability, revenue growth trajectory, leverage, and free cash flow generation, Crescent Biopharma, Inc. is rated at 4.7/10. This moderate-tier score shows mixed signals across our quality framework with notable weaknesses.

CirclFi runs 13 independent models for each stock. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every CBIO valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across CBIO's 1 active models, average confidence is 46%. Lower confidence may reflect limited history or high volatility.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Crescent Biopharma, Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Biotechnology Stocks Should You Also Analyze?

11 related Biotechnology stocks with 13-model coverage

EWTXEdgewise Therapeutics, Inc.QOC 4.7RZLTRezolute, Inc.QOC 4.7MISTMilestone Pharmaceuticals Inc.QOC 4.7HSTCHST Global, Inc.QOC 4.7MOLNMolecular Partners AGQOC 4.7CLRBCellectar Biosciences, Inc.QOC 4.7VORVor Biopharma Inc.QOC 3.8ASNDAscendis Pharma A/SQOC 6.5ANEBAnebulo Pharmaceuticals, Inc.QOC 5.4EXELExelixis, Inc.QOC 9.6INCYIncyte CorporationQOC 9.5

Read investment analysis: EWTX · RZLT · MIST · HSTC · MOLN · CLRB · VOR · ASND · ANEB · EXEL · INCY

Which Other Stocks Have a Similar Quality Score to CBIO?

5 companies across all industries closest to CBIO’s Quality of Company score of 4.7/10.

AIXNAiXin Life International, Inc.QOC 4.7PRFXPRF Technologies Ltd.QOC 4.7CCNBCoastal Carolina Bancshares, Inc.QOC 4.7GHSTGHST World Inc.QOC 4.7NVDANVIDIA CorporationQOC 10.0

Read investment analysis: AIXN · PRFX · CCNB · GHST · NVDA

Where Does CBIO Sit in CirclFi's Biotechnology Rankings?

CBIO is ranked against every other Biotechnology stock CirclFi covers in each of these screens.

See all Biotechnology stocks ranked →

What Else Do Investors Ask About Crescent Biopharma, Inc.’s Valuation?

What is Crescent Biopharma, Inc.'s intrinsic value in 2026?

CirclFi does not yet have enough active models to publish a median fair value for Crescent Biopharma, Inc. (CBIO). The Quality of Company score is 4.7/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is CBIO overvalued or undervalued right now?

At $17.75, 0 of 1 active models suggest CBIO may be undervalued, while 1 indicate potential overvaluation. The assessment depends on which methodology best fits Crescent Biopharma, Inc.'s business model in Biotechnology.

What does a Quality of Company score of 4.7 mean for CBIO?

Crescent Biopharma, Inc.'s QOC of 4.7/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores below 5 flag potential fundamental weaknesses requiring careful analysis.

How many valuation models does CirclFi run on CBIO?

CirclFi analyzes CBIO with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 1 of 13 are active for this stock. Read the full methodology →

Is CBIO a value trap in 2026?

Crescent Biopharma, Inc.'s Value Trap score is 32/100 (LOW). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap. Browse stocks by value-trap risk →

Cite this analysis — “CirclFi assigns Crescent Biopharma, Inc. (CBIO) a Quality of Company score of 4.7/10 across 32 fundamental signals as of 2026-08-28.” Source: circlfi.com/stock/CBIO/ · Methodology
Primary sources for this CBIO valuation
  • Financial statements: Crescent Biopharma, Inc. 10-K and 10-Q filings on SEC EDGAR (CIK 0001253689) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for CBIO as of ; valuations recomputed .